The stock has a 36-month beta value of 1.74. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for QNRX is 1.12M, and at present, short sellers hold a 36.64% of that float. On January 28, 2025, the average trading volume of QNRX was 2.46M shares.
QNRX) stock’s latest price update
The stock price of Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX) has plunged by -6.42 when compared to previous closing price of 0.34, but the company has seen a -48.03% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-23 that ASHBURN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces further clinical evidence of the potential efficacy of QRX003 in Netherton Syndrome.
QNRX’s Market Performance
Quoin Pharmaceuticals Ltd ADR (QNRX) has experienced a -48.03% fall in stock performance for the past week, with a -34.22% drop in the past month, and a -61.64% drop in the past quarter. The volatility ratio for the week is 23.30%, and the volatility levels for the past 30 days are at 15.07% for QNRX. The simple moving average for the last 20 days is -43.96% for QNRX stock, with a simple moving average of -50.49% for the last 200 days.
QNRX Trading at -48.13% from the 50-Day Moving Average
After a stumble in the market that brought QNRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.84% of loss for the given period.
Volatility was left at 15.07%, however, over the last 30 days, the volatility rate increased by 23.30%, as shares sank -42.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.23% lower at present.
During the last 5 trading sessions, QNRX fell by -47.72%, which changed the moving average for the period of 200-days by -59.01% in comparison to the 20-day moving average, which settled at $0.5695. In addition, Quoin Pharmaceuticals Ltd ADR saw -50.96% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QNRX starting from Carter Denise P., who purchase 555,556 shares at the price of $0.45 back on Dec 23 ’24. After this action, Carter Denise P. now owns 602,648 shares of Quoin Pharmaceuticals Ltd ADR, valued at $250,000 using the latest closing price.
Myers Michael, the Chief Executive Officer of Quoin Pharmaceuticals Ltd ADR, purchase 555,556 shares at $0.45 during a trade that took place back on Dec 23 ’24, which means that Myers Michael is holding 602,808 shares at $250,000 based on the most recent closing price.
Stock Fundamentals for QNRX
Current profitability levels for the company are sitting at:
- -59.48 for the present operating margin
- 0.51 for the gross margin
The net margin for Quoin Pharmaceuticals Ltd ADR stands at -56.48. The total capital return value is set at -1.16. Equity return is now at value -136.11, with -66.14 for asset returns.
Currently, EBITDA for the company is -9.27 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of -8.89. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.02.
Conclusion
To sum up, Quoin Pharmaceuticals Ltd ADR (QNRX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
